Merkel cell carcinoma and melanoma are not the same disease. They arise from different cell types, are driven by different causes, look different under a microscope, respond to different treatments, and carry markedly different prognoses. Both are skin cancers, and both can be aggressive, which is where the confusion usually starts. But the similarities are largely superficial. A head-to-head comparison using U.S. cancer registry data found that people with Merkel cell carcinoma face roughly double the cancer-specific mortality risk compared to those with melanoma, underscoring just how different their clinical trajectories are.
Where the Confusion Comes From
If you search for “skin cancer,” the results tend to lump everything together: basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. All four grow on skin, all four can be worsened by sun exposure, and all four occasionally show up as pink or reddish bumps. Beyond that, Merkel cell carcinoma and melanoma share almost nothing. But because melanoma is by far the better-known aggressive skin cancer, people who hear “Merkel cell carcinoma” for the first time often assume it is a variant of melanoma or a close relative. It is neither.
Adding to the confusion, both cancers can occasionally appear in the same anatomical sites, and both tend to strike sun-exposed areas of fair-skinned individuals. Both can spread to lymph nodes early in the course of the disease. And both have benefited from the recent wave of immunotherapy drugs. These overlapping features give a misleading impression of kinship. Underneath, the biology is strikingly different.
Different Cells, Different Origins
Melanoma arises from melanocytes, the pigment-producing cells scattered throughout the deepest layer of the epidermis. Their job is to make melanin, the molecule that gives skin its color and offers some UV protection. When melanocytes accumulate enough DNA damage, usually from ultraviolet radiation, they can become malignant.
Merkel cell carcinoma was originally assumed to originate from Merkel cells, the touch-sensitive cells found near nerve endings in the skin. The name stuck, but the actual cell of origin turns out to be more complicated. Recent research suggests that virus-positive and virus-negative forms of the cancer may even arise from two entirely different cell types: virus-positive tumors possibly from dermal fibroblasts and virus-negative tumors from epidermal keratinocytes. If confirmed, this would make Merkel cell carcinoma unusual in that a single cancer diagnosis could trace back to cells from two distinct embryonic tissue layers.1Europe PMC / Nature Publishing Group. Are there multiple cells of origin of Merkel cell carcinoma? That kind of dual origin is, to put it mildly, not something melanoma shares.
A Virus Behind Most Cases
One of the starkest differences between Merkel cell carcinoma and melanoma is that roughly 80% of Merkel cell carcinoma cases are caused by a virus called Merkel cell polyomavirus. This virus is widespread in the general population and usually harmless. In rare cases, its DNA integrates into a host cell’s genome in a way that drives uncontrolled growth.2PubMed Central. Merkel Cell Polyomavirus (MCPyV) and Cancers: Emergency Bell or False Alarm? That integration event, not sunburn, is the primary trigger for most Merkel cell carcinomas.3PubMed Central. Merkel Cell Polyomavirus: Infection, Genome, Transcripts and Its Role in Development of Merkel Cell Carcinoma
Melanoma, by contrast, has no known viral cause. Its primary driver is ultraviolet radiation damage to melanocyte DNA, compounded by genetic predisposition in some families. There is a UV component to Merkel cell carcinoma too, but it plays a starring role mainly in the roughly 20% of cases that are virus-negative. Those virus-negative tumors carry a heavy load of UV-signature mutations, particularly a pattern of C-to-T changes in DNA that is the hallmark of sun damage. Virus-positive tumors show a much “flatter” mutational pattern, consistent with aging-related DNA changes rather than UV exposure.4PubMed Central. Mutational Landscape of Virus- and UV-Associated Merkel Cell Carcinoma Cell Lines Is Comparable to Tumor Tissue So even when UV does play a role in Merkel cell carcinoma, it is in a biologically distinct subset of the disease.
How They Look on the Skin
Melanoma is the skin cancer most people can picture: an irregularly shaped, often darkly pigmented mole that changes color, size, or shape. The well-known “ABCDE” criteria (Asymmetry, Border irregularity, Color variation, Diameter, Evolving) were developed specifically for melanoma and are taught widely.
Merkel cell carcinoma looks nothing like that. It typically presents as a firm, dome-shaped, painless nodule, usually pink, red, or violet, and rarely pigmented. It grows fast. Because it does not look alarming the way a dark irregular mole does, it is frequently mistaken for a cyst, a bug bite, or a benign growth. A landmark study of 195 patients identified a set of clinical features summarized by the acronym AEIOU: the lesion is Asymptomatic (not tender), Expanding rapidly, found in someone who is Immunosuppressed, Older than 50, and on a UV-exposed site in a fair-skinned person. Nearly 90% of primary Merkel cell carcinomas in that study had three or more of those features.5PubMed Central. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the “AEIOU” features
The problem is that none of those features screams “cancer” to a non-specialist. A painless bump on the arm of an older man does not usually prompt an urgent biopsy. This is one reason Merkel cell carcinoma is often diagnosed later than melanoma relative to its rate of growth.
Telling Them Apart Under the Microscope
When a pathologist examines a biopsy, the two cancers look and stain very differently. Merkel cell carcinoma cells are small, round, and blue, packed tightly together with a high ratio of nucleus to cytoplasm. They resemble other neuroendocrine tumors more than they resemble melanoma cells. Melanoma cells, meanwhile, tend to be larger, more variable in shape, and often contain melanin pigment granules.
Immunohistochemistry, the technique of staining tissue with antibodies that bind to specific proteins, makes the distinction even clearer. Merkel cell carcinoma cells reliably stain positive for cytokeratins 18 and 20, chromogranin A, and neuron-specific enolase. Melanoma cells are negative for all of those markers but stain positive for proteins called HMB45, NKI/C3, and S-100.6Dermatology. Differentiation between Merkel Cell Carcinoma and Malignant Melanoma: An Immunohistochemical Study The pattern is essentially a mirror image: what lights up in one cancer goes dark in the other. In cases where the diagnosis is uncertain on visual inspection alone, these stains reliably settle the question.7PubMed. Merkel cell carcinoma of the eyelid: histological and immunohistochemical features with special respect to differential diagnosis
Cytokeratin 20 deserves special mention. It stains positive in over 90% of Merkel cell carcinomas and was established as a highly specific diagnostic marker for the disease. In practice, CK20 positivity in a small-round-blue-cell tumor of the skin points strongly toward Merkel cell carcinoma and away from melanoma, lymphoma, or metastatic small-cell lung cancer.
Who Gets Each Cancer
Melanoma is relatively common. In the United States alone, more than 100,000 new cases are diagnosed each year. It can strike at any age, including young adults, and while fair skin is a strong risk factor, people with darker skin tones can and do develop it.
Merkel cell carcinoma is rare by comparison. Estimates place U.S. incidence at a few thousand cases per year, making it roughly 40 to 50 times less common than melanoma. It overwhelmingly affects older adults, with a median age at diagnosis near the late 70s, and it is far more common in men. A suppressed immune system is one of the strongest risk factors. People living with HIV have about 2.8 times the risk of the general population, those with chronic lymphocytic leukemia about 5.8 times the risk, and organ transplant recipients face a dramatically elevated risk, roughly 13 times that of the general population.8JAMA Dermatology. Merkel Cell Carcinoma and Immunosuppression, UV Radiation, and Merkel Cell Polyomavirus People with autoimmune conditions or lymphoproliferative diseases also face heightened risk.9PubMed Central. Merkel cell carcinoma in immunosuppressed patients
Immunosuppression matters in melanoma too, but the magnitude of the association is far less dramatic. The virus link in Merkel cell carcinoma helps explain why: a weakened immune system is less able to keep Merkel cell polyomavirus in check, so the virus has more opportunity to drive malignant transformation.
Prognosis and Survival
Despite being far less common, Merkel cell carcinoma is stage-for-stage more lethal than melanoma. A California Cancer Registry study found that one-year survival was about 93% for melanoma patients but only about 58% for those with Merkel cell carcinoma. At 10 years, cumulative survival was roughly 61% for melanoma compared to around 18% for Merkel cell carcinoma.10PubMed Central. A Comparison of Merkel Cell Carcinoma and Melanoma: Results from the California Cancer Registry A more recent national comparison found that cancer-specific mortality was about 2.3 times higher among Merkel cell carcinoma patients than among those with melanoma, though both groups saw improvement after 2011 when checkpoint inhibitor immunotherapies entered clinical use.11PubMed Central. A Comparative Study of Merkel Cell Carcinoma and Melanoma Incidence and Survival in the United States, 2000-2021
Part of the survival gap reflects how quickly Merkel cell carcinoma spreads. In one study tracking patterns of spread, about 59% of patients developed regional or distant metastases. Most initial spread went to nearby lymph nodes, but roughly a quarter of patients eventually developed disease in distant organs, most commonly in the abdominal organs and distant lymph nodes.12Europe PMC. Patterns of Metastasis in Merkel Cell Carcinoma Melanoma spreads too, but the path and pace tend to differ: melanoma more commonly seeds the lungs and brain early, whereas Merkel cell carcinoma rarely reaches the brain or lungs as a first distant site.
Treatment Differences
Surgery is the frontline treatment for localized disease in both cancers, but the specifics diverge. Melanoma has well-established surgical margin guidelines informed by multiple randomized trials correlating margin width with tumor depth. For Merkel cell carcinoma, the rarity of the disease means that margin recommendations are less well defined and are drawn mostly from retrospective data.13PubMed Central. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough? One analysis of 188 localized cases found that narrow margins (1 cm or less) led to local recurrence in 20% of patients treated with surgery alone, but when adjuvant radiation was added, recurrence dropped to just 1% regardless of margin width.14PubMed Central. Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm
Radiation plays a much bigger role in Merkel cell carcinoma than in melanoma. Merkel cell carcinoma is substantially more sensitive to radiation. Lab studies measuring how well tumor cells survive standard radiation doses found that Merkel cell carcinoma cell lines were killed much more effectively than melanoma cell lines, which are notoriously radiation-resistant.15International Journal of Radiation Oncology*Biology*Physics. Radiation sensitivity of merkel cell carcinoma cell lines In practice, this means radiation is frequently used after surgery for Merkel cell carcinoma, even in early-stage disease, in a way that is not standard for most melanomas.
Immunotherapy has transformed the outlook for advanced cases of both diseases, but the drugs involved are not always the same. For melanoma, both checkpoint inhibitors and BRAF-targeted therapies are used, depending on the tumor’s genetic profile. Merkel cell carcinoma does not have the BRAF mutations that melanoma does, so targeted therapy with BRAF and MEK inhibitors is not relevant. However, checkpoint inhibitors, drugs that release the brakes on the immune system, have proven effective. A meta-analysis pooling data from six clinical trials of immunotherapy in Merkel cell carcinoma reported an overall response rate of about 51%.16PubMed Central / Elsevier. Clinical impact of immunotherapy in Merkel cell carcinoma patients: A systematic review and meta-analysis That is an encouraging number for a cancer that historically had few good options once it spread.
When Merkel Cell Carcinoma Shows Up Without an Obvious Skin Tumor
An unusual feature of Merkel cell carcinoma that has no real parallel in melanoma is the surprisingly high rate of cases with no identifiable primary skin tumor. About 12% of patients in one large database were diagnosed after cancer was found in a lymph node, with no visible skin lesion to explain it.17SpringerLink / Annals of Surgical Oncology. Merkel Cell Carcinoma of Unknown Primary Origin These cases, sometimes called “unknown primary” Merkel cell carcinoma, may result from a primary tumor that spontaneously regressed or was too small to detect. Interestingly, the prognosis for patients with unknown primary MCC is relatively favorable compared to those with a known primary and nodal spread, possibly because the immune response strong enough to eliminate the skin lesion also works against the remaining cancer.
CK20 staining, the same marker used to identify Merkel cell carcinoma in skin biopsies, is equally useful in these cases. In the unknown-primary cohort, CK20 was positive in 93% of tumors tested, while thyroid transcription factor-1, a marker for lung cancer, was negative in all. That staining pattern helps oncologists distinguish a Merkel cell carcinoma node from metastatic small-cell lung cancer, which can look nearly identical under the microscope.
Imaging and Staging
Both cancers use PET/CT scans for staging, but Merkel cell carcinoma has an additional imaging option that melanoma does not. Because Merkel cell carcinoma tumors often express somatostatin receptors on their surface, scans using gallium-68-labeled somatostatin analogs can detect the disease. A comparison study in 15 patients found that both standard FDG-PET and somatostatin-analog PET detected disease with similar sensitivity, correctly identifying all positive patients, though they differed slightly in specificity.18PubMed Central. 18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study This dual-imaging approach could eventually help in tricky cases where conventional scans leave ambiguity, though the evidence base is still small.
Why the Distinction Matters for Patients
Getting the diagnosis right is not an academic exercise. A patient whose Merkel cell carcinoma is mistaken for melanoma could miss out on adjuvant radiation, which is a cornerstone of Merkel cell carcinoma management but not routinely used in early melanoma. They could receive BRAF-targeted therapy that has no relevance to their tumor. Their follow-up schedule, their screening for immune-related risk factors, and the conversation about prognosis would all be wrong. Conversely, a melanoma patient treated as if they had Merkel cell carcinoma could receive unnecessarily aggressive radiation while missing a targeted therapy that might benefit them.
For the patient sitting in the dermatologist’s office, the practical takeaway is straightforward: if a biopsy report says Merkel cell carcinoma, you are dealing with a rare neuroendocrine skin cancer that demands its own playbook. It is not a type of melanoma, not a subtype, and not a cousin. The name “cell carcinoma” versus “melanoma” is not just labeling. It reflects genuinely different biology, and the treatment plan should reflect that difference at every step.